FDA issued Emergency Use Authorization for second COVID-19 vaccine
On Dec. 18, 2020, the FDA issued an emergency use authorization (EUA) for the second vaccine for the…
On Dec. 18, 2020, the FDA issued an emergency use authorization (EUA) for the second vaccine for the…
On Dec. 18, 2020, Moderna announced that the European Commission (EC) had exercised its option to purchase an…
On Dec. 17, 2020, Moderna confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological…
On Dec. 14, 2020, Moderna confirmed that the Company had concluded an agreement with the Ministry of Health…
On Dec. 11, 2020, Moderna announced that the U.S. government has exercised its option to purchase an additional…
On Dec. 10, 2020, Roche announced a partnership with Moderna to utilise the Elecsys Anti-SARS-CoV-2 S antibody test…
On Dec. 9, 2020, Roche announced a partnership with Moderna to utilise the Elecsys Anti-SARS-CoV-2 S antibody test…
On Dec. 8, 2020, Moderna announced the Swiss Federal Government had increased its confirmed order commitment from 4.5…
On Dec. 7, 2020, Moderna announced that the Canadian Government had increased its confirmed order commitment by 20…
On Dec. 3, 2020, Moderna announced in a letter to the editor published in the New England Journal…
On Nov. 29, 2020, Moderna announced a supply agreement with the United Kingdom (UK) government for an additional…
On Nov. 25, 2020, Moderna announced that the European Commission (EC) has approved an agreement to secure 80…
On Nov. 20, 2020, researchers at the Broad Institute of MIT and Harvard announced they had developed a…
On Nov. 17, 2020, Moderna announced a supply agreement with the government of the United Kingdom (UK) to…
On Nov. 16, 2020, Moderna announced new data showing that mRNA-1273, its COVID-19 vaccine candidate, remained stable at…
On Nov. 16, 2020, Moderna announced that the European Medicines Agency (EMA) human medicines committee (CHMP) had started…
On Nov. 15, 2020, an independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of…
On Nov. 13, 2020, Moderna announced that Swissmedic had started a rolling review of mRNA-1273, the Company’s vaccine…
On Nov. 12, 2020, CureVac announced that its mRNA-based COVID-19 vaccine candidate, CVnCoV, remained stable and within defined…
On Nov. 11, 2020, Moderna announced that it had completed case accrual for the first interim analysis of…
On Nov. 9, 2020, Ultragenyx announced that it planned to build a new large-scale gene therapy manufacturing facility…
On Nov. 6, 2020, in a study published in Cell, the researchers identified antiviral defense genes that the…
On Oct. 29, 2020, AquaBounty Technologies announced that it had identified Mayfield, Kentucky as the potential location for…
On Oct. 29, 2020, Takeda Pharmaceutical announced that it would import and distribute 50 million doses of Moderna’s…
On Oct. 27, 2020, Moderna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
On Oct. 27, 2020, researchers at Yale University and the Broad Institute of MIT and Harvard screened hundred…
On Oct. 26, 2020, Moderna announced a supply agreement with the Ministry of Public Health of Qatar for…
On Oct. 22, 2020, Moderna announced that it had completed enrollment of 30,000 participants for the Phase 3…
On Oct. 19, 2020, researchers at MIT, Harvard, and the Broad Institute of MIT announced they had developed…
On Oct. 14, 2020, Moderna announced that it had received written confirmation from the European Medicines Agency (EMA)…